Finally, a novel non-bile acid class FXR agonist containing steroid and non-steroid components was recently shown to reduce liver fat in non-cirrhotic patients with fibrotic NASH at 2.5 mg/d. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.